Your session is about to expire
← Back to Search
Radiation Therapy
GRID Therapy for Advanced Cancer
N/A
Recruiting
Led By Te Vuong, MD
Research Sponsored by Sir Mortimer B. Davis - Jewish General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Patient planned to undergo palliative radiation therapy treatments to one of the following 5 sites: extremities, neck, chest, abdomen and pelvis
WHO performance status of 0-2
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3, 6, 9, 12 months
Awards & highlights
Study Summary
This trial is testing a new way of giving radiation therapy to people with tumors that are hard to treat. The new method is called spatially fractionated radiation (SFR). It delivers one single treatment through a grid containing holes. The goal of the trial is to see if SFR is a safe and effective way to palliate patients with symptomatic bulky tumors.
Who is the study for?
This trial is for adults aged 18+ with confirmed malignancies, who have bulky tumors larger than 8cm or tumors resistant to radiation like melanoma. It's also for those previously treated with palliative radiation needing more than one fraction. Patients must be able to consent and have a WHO performance status of 0-2. Pregnant women, patients with brain/spinal cord tumors, previous hypofractionated radiation therapy, or curable conditions are excluded.Check my eligibility
What is being tested?
The trial tests spatially fractionated radiation therapy (SFR) as a single-session treatment through a grid for symptomatic bulky or radioresistant tumors. The goal is to validate SFR's safety and effectiveness compared to traditional multiple-session palliative treatments that can cause significant toxicity.See study design
What are the potential side effects?
While the side effects specific to SFR aren't detailed here, typical side effects from similar palliative radiation therapies may include skin reactions at the treatment site, fatigue, nausea, and potential damage to nearby organs depending on tumor location.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am scheduled for radiation therapy on my limbs, neck, chest, abdomen, or pelvis for symptom relief.
Select...
I can take care of myself and perform light activities.
Select...
I am 18 years old or older.
Select...
My tumor is larger than 8cm, resistant to radiation, or was previously treated with radiation.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 3, 6, 9, 12 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3, 6, 9, 12 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Symptom relief, as measured using the CTCAE grading system (v4.0) and pain questionnaire
Secondary outcome measures
Acute toxicity of treatment, as measured using the CTCAE grading system (v4.0)
Cost-effectiveness, as measured by evaluating the cost of the procedure per patient and the efficacy of treatment with regards to symptom relief and tumor response
Long-term toxicity of treatment, as measured using the CTCAE grading system (v4.0)
+1 moreTrial Design
1Treatment groups
Experimental Treatment
Group I: GRID radiation therapyExperimental Treatment1 Intervention
A single dose of 15-20Gys of spatially fractionated radiation therapy
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Radiation therapy, including Spatially Fractionated Radiation (SFR), works by damaging the DNA of cancer cells, preventing their replication and causing cell death. SFR delivers a single high-dose of radiation through a grid, focusing on bulky or radioresistant tumors.
This approach reduces toxicity, minimizes hospital visits, and improves patient quality of life by sparing healthy tissue while effectively targeting the tumor.
State-of-the-art and emerging treatment options in the management of head and neck cancer: news from 2013.
State-of-the-art and emerging treatment options in the management of head and neck cancer: news from 2013.
Find a Location
Who is running the clinical trial?
Sir Mortimer B. Davis - Jewish General HospitalLead Sponsor
55 Previous Clinical Trials
21,110 Total Patients Enrolled
Te Vuong, MDPrincipal InvestigatorSir Mortimer Jewish General Hospital
6 Previous Clinical Trials
387 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have had radiation therapy aimed at easing symptoms.My tumor is near the spinal cord or in the brain.I am scheduled for radiation therapy on my limbs, neck, chest, abdomen, or pelvis for symptom relief.I can take care of myself and perform light activities.I am 18 years old or older.My cancer diagnosis was confirmed through lab tests.My tumor is larger than 8cm, resistant to radiation, or was previously treated with radiation.
Research Study Groups:
This trial has the following groups:- Group 1: GRID radiation therapy
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger